First patient treated in phase 2 obesity trial of GLY-200 polymerGlyscend Therapeutics has initiated a Phase 2 clinical trial of its lead candidate, GLY-200, as a novel oral treatment for obesity....
Metabolic benefits of oral polymer-based duodenal exclusion therapyGlyscend Therapeutics has presented preclinical study results at EASD 2021 evaluating the metabolic effects of once-daily oral therapy in...
LSG with Nissen Fundoplication has higher prevalence of comorbidities and a longer hospital length of stay3 hours ago